8-K Announcements
6Material company update
Apr 1, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 6, 2026·SEC
Cyclerion Therapeutics, Inc.(CYCN)Earnings, Financials & Key Ratios
CYCN•NASDAQ
$3.37
Price updated Jul 2, 2026
AboutCyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$2M+3.7%
- EBITDA-$5M-37.1%
- Net Income-$4M-15.4%
- EPS (Diluted)-1.09+9.9%
- Gross Margin100%
- EBITDA Margin-239.78%-32.2%
- Operating Margin-239.78%-32.2%
- Net Margin-170.11%-11.3%
- ROE-39.34%-29.6%
CYCN Price & Volume
Cyclerion Therapeutics, Inc. (CYCN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Burn Threatens Clinical Pipeline Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and insolvency
Key Thesis Takeaways
- Cyclerion Therapeutics faces a precarious financial outlook characterized by a lack of sustainable revenue, as evidenced by the 100% revenue contraction in 2026Q1.
- The company's reliance on sporadic milestone payments to fund its sGC stimulator pipeline is insufficient to cover persistent SG&A expenses that frequently exceed $1.5 million per quarter.
- Investors should remain cautious as the firm's cash reserves have dwindled to $2.8 million, creating significant liquidity risks that may necessitate dilutive financing to maintain operations.
Verdict Logic
the company's cash runway is nearing a critical threshold with only $2.8 million in cash remaining as of 2026Q1, which is insufficient to support ongoing operational burn without immediate external intervention.
CYCN Growth Metrics
Cyclerion Therapeutics, Inc. (CYCN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-2.01%
3 Years91.14%
TTM-4.23%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-79.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-21.37%
Return on Capital
10 Years-81.22%
5 Years-69.81%
3 Years-70.21%
Last Year-55.46%
CYCN Recent Earnings
Cyclerion Therapeutics, Inc. (CYCN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (86%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.76+95.6%
$17.20
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.19+50.0%
$0.38
Rev
$100,000+0.0%
$100,000
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.38+0.0%
$0.38
Rev
$100,000+0.0%
$100,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.30
—
Rev
$875,000
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.76vs $17.20+95.6% | — |
| Q2 2026 | Mar 30, 2026 | $0.19vs $0.38+50.0% | $100,000vs $100,000+0.0% |
| Q2 2026 | Mar 25, 2026 | $0.38vs $0.38+0.0% | $100,000vs $100,000+0.0% |
| Q4 2025 | Nov 12, 2025 | $0.30 | $875,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cyclerion Therapeutics, Inc. (CYCN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.37 | $14.59M | -3.09 | 3.7% | -170.11% | -39.34% | — | |
| $8.61 | $2B | 14.35 | 19.63% | 32.43% | 38.97% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $1.78 | $39.04M | -0.54 | — | — | -1335.64% | — | |
| $9.58 | $501.54M | -2.11 | -92.84% | -260.92% | -49.88% | — | |
| $4.05 | $1.25B | 202.50 | 22.23% | -6.63% | — | — |
Compare CYCN vs Peers
Cyclerion Therapeutics, Inc. (CYCN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CYCN SEC Filings & Documents
Cyclerion Therapeutics, Inc. (CYCN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CYCN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CYCN Frequently Asked Questions
Cyclerion Therapeutics, Inc. (CYCN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cyclerion Therapeutics, Inc.'s revenue?
Cyclerion Therapeutics, Inc. (CYCN) reported $2.0M in revenue for fiscal year 2025.
How fast is Cyclerion Therapeutics, Inc. growing?
Cyclerion Therapeutics, Inc. (CYCN) grew revenue by 3.7% over the past year. Growth has been modest.
Is CYCN profitable?
Cyclerion Therapeutics, Inc. (CYCN) reported a net loss of $5.3M for fiscal year 2025.
Dividend & Returns
What is CYCN's return on equity?
Cyclerion Therapeutics, Inc. (CYCN) has a return on equity (ROE) of -39.3%. Negative ROE indicates the company is unprofitable.
What is Cyclerion Therapeutics, Inc.'s free cash flow?
Cyclerion Therapeutics, Inc. (CYCN) had negative free cash flow of $3.6M in fiscal year 2025, likely due to heavy capital investments.